Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

Rhea-AI Summary

Impact BioMedical Inc. (NYSE American: IBO) has successfully completed its Initial Public Offering (IPO). The biotechnology company, focused on discovering, developing, and patenting innovative healthcare solutions, saw strong support from existing investors, who purchased over 30% of the IPO shares. This significant participation demonstrates confidence in the company's mission and potential.

Frank D. Heuszel, CEO of Impact BioMedical, expressed that the substantial involvement of existing investors underscores their belief in the company's work and its potential to make a meaningful impact on human health. The successful IPO marks an important milestone for Impact BioMedical as it continues its efforts in developing innovative healthcare solutions.

Positive

• Successful completion of Initial Public Offering (IPO)
• Over 30% of IPO shares purchased by existing investors
• Strong investor confidence in the company's mission and potential

Negative

• None.

News Market Reaction – IBO

+5.50%

1 alert

+5.50% News Effect

On the day this news was published, IBO gained 5.50%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

HOUSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, is pleased to announce the successful completion of its Initial Public Offering (IPO). Notable is that over 30% of the IPO was purchased by existing investors which further demonstrates strong belief in the company and its potential.

Frank D. Heuszel, CEO of Impact BioMedical, commented, "The significant participation of our investors underscores their confidence in our mission and the innovative healthcare solutions we are developing. Their support is a testament to the value they see in our work and our potential to make a meaningful impact on human health."

About Impact BioMedical, Inc.:

Impact BioMedical Inc. (NYSE American: IBO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.

Media Contact:
Mark Suseck Email: mark.suseck@impactbiomedinc.com

Investor Relations:
info@impactbiomedinc.com

FAQ

What percentage of Impact BioMedical's (IBO) IPO was purchased by existing investors?

Over 30% of Impact BioMedical's (IBO) IPO was purchased by existing investors, demonstrating strong confidence in the company's mission and potential.

When did Impact BioMedical (IBO) complete its Initial Public Offering?

Impact BioMedical (IBO) announced the successful completion of its Initial Public Offering on October 7, 2024.

What is Impact BioMedical's (IBO) focus as a biotechnology company?

Impact BioMedical (IBO) is dedicated to discovering, developing, and patenting innovative healthcare solutions.

What stock exchange is Impact BioMedical (IBO) listed on?

Impact BioMedical (IBO) is listed on the NYSE American stock exchange.